Retatrutide Price

Retatrutide is an investigational once-weekly injectable medication being developed by Eli Lilly to treat obesity, overweight, and type 2 diabetes. However, It is not yet approved for general use by major regulatory agencies and remains in clinical development. Retatrutide is and important medications that helps the body in different problems like increasing energy, and reducing appetide etc. What makes retatrutide different is that it targets three hormone receptors at the same time:

• GLP-1 – reduces appetite, slows stomach emptying, and helps control blood sugar.
• GIP – enhances insulin release and supports metabolic regulation.
• Glucagon – increases energy expenditure and promotes fat burning.

Because it acts on all three pathways, it is often called a triple hormone receptor agonist or “triple agonist”. Although retatrutide has generated significant interest because of its weight-loss results, it should not be purchased from unapproved online sources. Products marketed as retatrutide outside authorized clinical trials may not contain the stated ingredient or may be contaminated. Retatrutide is not yet commercially approved in most countries, so there is no official retail price from a manufacturer or pharmacy. Current prices you may see online are generally for research-use products, which are not approved for human use and can vary widely in quality and legality.

Typical research-market prices in 2026 are approximately:

• 5 mg vial: US$100–180
• 10 mg vial: US$150–300
• 15 mg vial: US$200–400

Retatrutide Price Per Month

Retatrutide peptide is a highly effective medication that it is been used by people worldwide although it is not yet approved by the FDA. In addition, retatrutide is not yet commercially approved, there is no official monthly retail price. Based on analyst expectations and pricing of similar medications, the expected monthly cost after approval is:

• US list price (without insurance): $1,000–$1,400 per month
• With manufacturer discount programs (if available): $500–$700 per month
• With insurance coverage (where applicable): Often $25–$150 per month, depending on the health plan and eligibility.

Currently, some websites sell research or compounded retatrutide for approximately $200–$600 per month, but these are not approved commercial products, are generally not covered by insurance, and their quality and safety may vary. Based on the clinical data available so far, it has the potential to be one of the most effective weight-loss medications developed. In recent Phase 3 results, participants lost an average of about 28% of their body weight over 80 weeks, with many achieving at least 30% weight loss—results approaching those seen with bariatric surgery.

Retatrutide Price In USA

Retatrutide Price depends on your health goals, your risk of obesity-related disease, and what you’ll actually pay out of pocket. The final price will depend on the country, regulatory approvals, insurance coverage, and any patient assistance programs offered when it launches. At present, Eli Lilly has not announced an official retail price. For many people, the biggest factor will not be how well the drug works, but whether insurance or a national health system covers it. A highly effective medication can still be poor value if it is unaffordable, while the same medication can be excellent value if most of the cost is covered. As of August 2026, retatrutide price is not approved in the United States, so there is no official U.S. retail price. Eli Lilly has announced plans to file for FDA approval in early 2027, and the drug would only receive an official U.S. price if and when it is approved.

For comparison:

• Zepbound (tirzepatide): around $1,000+ per month at list price.
• Wegovy (semaglutide): around $1,300+ per month at list price, though discounts and insurance can significantly reduce out-of-pocket costs. If retatrutide delivers the weight-loss results seen in clinical trials and launches successfully, many analysts expect its U.S. pricing to be competitive with these existing GLP-1–based therapies rather than dramatically higher. However, Eli Lilly has not announced an official U.S. price.